Clinical Trial: Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21)

U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07888569) titled 'Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21)' on Sept. 30.

Brief Summary: This study is a phase 1, open-label, three-period crossover study to evaluate the effect of Rabeprazole, a proton pump inhibitor, on the pharmacokinetics of DZD8586 (Birelentinib) under fasted and fed conditions in healthy participants.

Study Start Date: Oct. 16

Study Type: INTERVENTIONAL

Condition: Healthy

Intervention: DRUG: DZD8586

DZD8586 administered by mouth as a single dose in Period 1 (without food), Period 2 (with rabeprazole with food) and Period 3 (with rabeprazole wit...